Patent application number | Description | Published |
20090149509 | NOVEL PYRROLIDINE BICYCLIC COMPOUNDS AND ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE - N-[1-oxo-(optionally 2-aza)-2-alkyl-3-(carboxyl or thiol or hydroxyaminocarbonyl or N-hydroxyformamido)-propyl]-(aryl or heteroaryl)-azacyclo | 06-11-2009 |
20100063278 | N-Formyl Hydroxylamines compounds - Novel N-formyl hydroxylamine compounds and their derivatives are discloses. These N-formyl hydroxylamine compounds inhibit peptidyl deformylase (PDF), an enzyme present in prokaryotes. The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and use of the compounds are also disclosed. | 03-11-2010 |
20100137349 | ANTIMICROBIAL OXAZOLIDINONE, HYDANTOIN AND IMIDAZOLIDINONE COMPOSITIONS - The present application relates to N-chlorinated oxazolidinone, hydantoin and imidazolidinone compounds of Formula I | 06-03-2010 |
20100158818 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS - The present application relates to N-chlorinated cationic compounds of Formula I | 06-24-2010 |
20110151025 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections - Disclosed herein are methods and compositions for the treatment or prophylaxis, in a mammal, of bronchopulmonary infections, obstructive pulmonary disease, cystic fibrosis, and ventilator-associated infections. The methods and compositions include a therapeutically effective amount of one or more N-halogenated or N,N-dihalogenated amines, and their analogues, derivatives, or pharmaceutically acceptable salts and esters. | 06-23-2011 |
Patent application number | Description | Published |
20090016962 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - Provided are nanostructures comprising a charged outer surface and an inner core comprising a cancer therapeutic agent or imaging agent, wherein the charged outer surface is selectively removable. Further provided are methods of treating subjects having cell proliferative disorders, e.g., cancer, and kits comprising the above nanostructures. | 01-15-2009 |
20100087370 | MODULATION OF NITRIC OXIDE SIGNALING TO NORMALIZE TUMOR VASCULATURE - The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject. | 04-08-2010 |
20120237567 | MODULATING LYMPHATIC FUNCTION - Methods and compositions for modulating lymphatic function, e.g., by altering NO levels, are disclosed. | 09-20-2012 |
20130195926 | MODULATION OF NITRIC OXIDE SIGNALING TO NORMALIZE TUMOR VASCULATURE - The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject. | 08-01-2013 |
20130216531 | ANTI-CXCR4 AS A SENSITIZER TO CANCER THERAPEUTICS - Inhibition of CXCR4 can inhibit tumor growth and metastasis during certain therapeutic windows. Disclosed are novel methods for treating and preventing cancer in a subject related to administration of CXCR4 inhibitors during a therapeutic window following treatment with another anti-tumor therapy. | 08-22-2013 |
20130224282 | Multistage Nanoparticles - Multistage nanostructures, e.g., for delivery of agents such as imaging agents and therapeutic agents to tumor vasculature. | 08-29-2013 |
20140161720 | TREATMENT OF ANGIOGENIC- OR VASCULAR-ASSOCIATED DISEASES - Described herein are methods and compositions comprising a compound of formula (I), e.g., dehydro-alpha-lapachone, or an analog, derivative, isomer, prodrug, or pharmaceutically acceptable salt thereof, for treatment and/or prevention of angiogenic- or vascular-associated diseases or disorders. The compound has anti-vascular activity. In some embodiments, the compound has anti-vascular activity that targets pathways other than VEGF pathways. In some embodiments, the compound or the composition further comprises anti-tumor activity. In some embodiments, the compound or the composition can decrease adhesion or motility of at least one cell (e.g., endothelial cells or cancer cells). | 06-12-2014 |
20140161884 | Multistage Nanoparticle Drug Delivery System for the Treatment of Solid Tumors - Nanoparticles for a selective, two stage delivery to tumors have been developed. The nanoparticles are initially sized so that they preferentially accumulate in the tumor tissue as a result of leakage through the defective vascular in the solid tumors. Once in the tumor tissue, the nanoparticles are cleaved hydrolytically and/or by enzymatic cleavage over time to release smaller nanoparticles carrying therapeutic, prophylactic or diagnostic agents into the necrotic interior of the tumors. This provides a simple, elegant and highly effective means of delivery drug selectively not just to tumors generally, but, more importantly, into the poorly vascularized necrotic interiors which drugs are normally unable to penetrate. The nanoparticles have a number of advantages: less toxicity due to selective accumulation only in the tumors; access into the poorly vascularized necrotic interiors of the tumor; and sustained release over a period of time within the tumor. | 06-12-2014 |